{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:08:07Z","timestamp":1774645687191,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibrodysplasia ossificans progressiva (FOP) is an ultrarare condition and one of the most impactful disorders associated with progressive heterotopic ossification events. It is estimated that there are 120\u2013150 patients in Brazil; however, currently, fewer than 100 patients have been identified, and the role of a FOP advocacy group (FOP Brazil) has been instrumental for the identification and follow-up of these individuals and families. The aim of this article is to summarize the current status of FOP in Brazil and describe strategies proposed to approach this challenge in a continental size country.\n<\/jats:p>","DOI":"10.1186\/s13023-022-02503-6","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:05:30Z","timestamp":1662548730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fibrodysplasia ossificans progressiva in Brazil: challenges and strategies to create assistance and educational networks"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0026-2724","authenticated-orcid":false,"given":"Alessandro Rozim","family":"Zorzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia R.","family":"Delai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique L. C.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wander E.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor A. M.","family":"Montalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana C.","family":"Napimoga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo H.","family":"Napimoga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Francisco H.","family":"Nociti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"2503_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.20868","volume":"30","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, K\u00f6ster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30:379\u201390.","journal-title":"Hum Mutat"},{"key":"2503_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11914-011-0046-3","volume":"9","author":"E Shore","year":"2011","unstructured":"Shore E, Kaplan FS. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva. Curr Osteoporos Rep. 2011;9:83\u20138.","journal-title":"Curr Osteoporos Rep"},{"key":"2503_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2106\/00004623-199302000-00008","volume":"75","author":"RB Cohen","year":"1993","unstructured":"Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zaslo M, Kaplan FS. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressive. A study of forty-four patients. J Bone Joint Surg Am. 1993;75:215\u20139.","journal-title":"J Bone Joint Surg Am"},{"key":"2503_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/qjmed\/89.6.445","volume":"89","author":"R Smith","year":"1996","unstructured":"Smith R, Athanasou NA, Vipond SE. Fibrodysplasia (myositis) ossificans progressiva: clinicopathological features and natural history. QJM. 1996;89:445\u20136.","journal-title":"QJM"},{"key":"2503_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthr\u00f6m M, Durbin-Johnson BP, Shore EM, Rocke DM, Kaplan FS. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31:650\u20136.","journal-title":"J Bone Miner Res"},{"key":"2503_CR6","doi-asserted-by":"publisher","first-page":"e122958","DOI":"10.1172\/jci.insight.122958","volume":"15","author":"E Barruet","year":"2018","unstructured":"Barruet E, Morales BM, Cain CJ, Ton AN, Wentworth KL, Chan TV, Moody TA, Haks MC, Ottenhoff TH, Hellman J, Nakamura MC, Hsiao EC. NF-\u03baB\/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight. 2018;15:e122958.","journal-title":"JCI Insight"},{"key":"2503_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/sctm.16-0363","volume":"6","author":"C Lo Sicco","year":"2017","unstructured":"Lo Sicco C, Reverberi D, Balbi C, Ulivi V, Principi E, Pascucci L, Becherini P, Bosco MC, Varesio L, Franzin C, Pozzobon M, Cancedda R, Tasso R. Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-anflammatory effects: endorsement of macrophage polarization. Stem Cells Transl Med. 2017;6:1018\u201328.","journal-title":"Stem Cells Transl Med"},{"key":"2503_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-1-4939-8904-1_18","volume":"1891","author":"SA Chakkalakal","year":"2019","unstructured":"Chakkalakal SA, Shore EM. Heterotopic ossification in mouse models of fibrodysplasia ossificans progressiva. Methods Mol Biol. 2019;1891:247\u201355.","journal-title":"Methods Mol Biol"},{"key":"2503_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/dvdy.24606","volume":"247","author":"M LaBonty","year":"2018","unstructured":"LaBonty M, Yelick PC. Animal models of fibrodysplasia ossificans progressive. Dev Dyn. 2018;247:279\u201388.","journal-title":"Dev Dyn"},{"key":"2503_CR10","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jbmr.2820","volume":"31","author":"SA Chakkalakal","year":"2016","unstructured":"Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, Pacifici M, Iwamoto M, Shore EM. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation. J Bone Miner Res. 2016;31:1666\u201375.","journal-title":"J Bone Miner Res"},{"key":"2503_CR11","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1542\/peds.2005-0469","volume":"116","author":"JA Kitterman","year":"2005","unstructured":"Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116:e654-661.","journal-title":"Pediatrics"},{"key":"2503_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.29245\/2572-9411\/2020\/2.1196","volume":"5","author":"M Liljesthr\u00f6m","year":"2020","unstructured":"Liljesthr\u00f6m M, Pignolo RJ, Kaplan FS. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J Rare Dis Res Treat. 2020;5:31\u20136.","journal-title":"J Rare Dis Res Treat"},{"key":"2503_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16:350.","journal-title":"Orphanet J Rare Dis"},{"key":"2503_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat G, Choquet R, Bouee S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12:123.","journal-title":"Orphanet J Rare Dis"},{"key":"2503_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525\u20137.","journal-title":"Nat Genet"},{"key":"2503_CR16","first-page":"329","volume-title":"PKU screening in Brazil","author":"J-P Farriaux","year":"1994","unstructured":"Farriaux J-P, Dhondt JL. New horizons in neonatal screening. In: Schmidt BJ, editor. PKU screening in Brazil. Amsterdam: Excerpta Meedica; 1994. p. 329."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02503-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T22:04:35Z","timestamp":1662588275000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2503"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02503-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}